Abstract:Objective To explore the efficacy and safety of deferasirox in aplastic anemia(AA) patients with iron overload. Methods A single arm, multi-center, prospective, open-label study was conducted to evaluate absolute change in serum ferritin(SF)from baseline to 12 months of deferasirox administration, initially at a dose of 20 mg · kg-1 · d-1, and the safety in 64 AA patients with iron overload. Results All patients started their deferasirox treatment with a daily dose of 20 mg · kg-1 · d-1. The mean actual dose was(18.6 ± 3.60)mg · kg-1 · d-1. The median SF decreased from 4 924(2 718-6 765)μg/L at baseline (n=64) to 3 036(1 474-5 551)μg/L at 12 months (n=23) with the percentage change from baseline as 38%. A median SF decrease of 651(126-2 125)μg/L was observed at the end of study in 23 patients who completed 12 months’treatment, the median SF level decreased by 1 167(580-4 806)μg/L[5 271(3 420-8 278)μg/L at baseline;3 036(1 474-5 551)μg/L after 12 months’treatment;the percentage change from baseline as 42%]after 12 months of deferasirox treatment. The most common adverse events (AEs)were increased serum creatinine levels(40.98%), gastrointestinal discomfort(40.98%), elevated liver transaminase(ALT:21.31%;AST:13.11%)and proteinuria(24.59%). The increased serum creatinine levels were reversible and non-progressive. Of 38 patients with concomitant cyclosporine use, 12(31.8%) patients had two consecutive values>ULN, 10(26.3%)patients had two consecutive values>1.33 baseline values, but only 1(2.6%)patient’s serum creatinine increased more than 1.33 baseline values and exceeded ULN. For both AST and ALT, no patients experienced two post-baseline values >5 × ULN or >10 × ULN during the whole study. In AA patients with low baseline PLT count(less than 50 × 109/L), there was no decrease for median PLT level during 12 months’treatment period. Conclusions AA patients with iron overload could achieve satisfactory efficacy of iron chelation by deferasirox treatment. The drug was well tolerated with a clinically manageable safety profile and no major adverse events.

Studies on the protective effect of deferiprone against aluminum-induced heart damage in rats

Cytoprotective effect of deferiprone against aluminum chloride-induced oxidative stress and apoptosis in lymphocytes

Suppressive Effects of Subchronic Aluminum Overload on the Splenic Immune Function May Be Related to Oxidative Stress in Mice.

Deferoxamine Affects Heat Shock Protein Expression in Heart after Intracerebral Hemorrhage in Aged Rats

Investigation of the Effect of Omega-3 Fatty Acids on Antioxidant System and Serum Aluminum, Zinc, and Iron Levels in Acute Aluminum Toxicity

Deferiprone Protects the Isolated Atria from Cardiotoxicity Induced by Doxorubicin

Effect of the oral iron chelator deferiprone in diabetic nephropathy rats

Taurine and deferiprone against Al-linked apoptosis in rat hippocampus

Deferiprone–resveratrol hybrid attenuates iron accumulation, oxidative stress, and antioxidant defenses in iron-loaded human Huh7 hepatic cells

Lactobacillus plantarum CCFM639 Alleviate Trace Element Imbalance-Related Oxidative Stress in Liver and Kidney of Chronic Aluminum Exposure Mice

Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine

Development Of The Studies On The Aluminum Intoxication In The Pathology Of Alzhmer'S Disease, Parkinson'S Disease And Dialysis Diseases And On The Drugs Unloading Aluminum In Human Body

New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis

A novel synthetic compound, deferiprone-resveratrol hybrid (DFP-RVT), promotes hepatoprotective effects and ameliorates iron-induced oxidative stress in iron-overloaded β-thalassemic mice

Iron Dyshomeostasis Participated in Rat Hippocampus Toxicity Caused by Aluminum Chloride

The effectiveness of deferasirox to prevent from the occurrence of liver fibrosis in balb/c mice with iron overload

Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice

Efficacy and Safety of Deferasirox in Aplastic Anemia Patients with Iron Overload:A Single Arm, Multi-Center, Prospective Study in China

Comparison Between Hesperidin, Coumarin, and Deferoxamine Iron Chelation and Antioxidant Activity Against Excessive Iron in the Iron Overloaded Mice

Clinical Investigation of Dependent-Transfusion Iron Overload in Patients with Myelodysplastic Syndromes and Primary Myelofibrosis

The therapeutic protection of a living and dead Lactobacillus strain against aluminum-induced brain and liver injuries in C57BL/6 mice.